COMMUNIQUÉS West-GlobeNewswire

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
12/08/2024
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial [...]
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX ® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with FDA [...]
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
Following FDA consultation, announced plans for validation of the Gen-2 Optejet ® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of [...]
Biora Therapeutics Announces Funding Agreement with Existing Investors
12/08/2024
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining [...]
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
12/08/2024
Initiated dosing of ORIC-944 in combinations with NUBEQA ® (darolutamide) and ERLEADA ® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements [...]
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/08/2024
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]
Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12/08/2024
BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that president and chief scientific officer Wesley Jackson, [...]
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
12/08/2024
BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12/08/2024
Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call [...]
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent [...]
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
12/08/2024
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable [...]
Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024
12/08/2024
In connection with the consummation of the merger, the Company closed $3.5 million private placement offering FAIRFAX, Va. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “ [...]
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
12/08/2024
Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been submitted to the FDA [...]
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12/08/2024
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million [...]
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12/08/2024
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 [...]
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
12/08/2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy [...]
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
12/08/2024
BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial [...]
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
12/08/2024
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024
12/08/2024
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. “We [...]

Pages